Our Case No.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

plication of:

Ashkenazi et al.

Serial No.: 09/944,862

Filing Date: August 31, 2001

For:

SECRETED AND

TRANSMEMBRANE

POLYPEPTIDES AND NUCLEIC ACIDS ENCODING THE SAME

Examiner: To be assigned

Group Art Unit No.: 1645

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Washington, D.C. 20231

Dear Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed below and on the attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

The references now cited are the following:

OTHER ART

- 1. Blast Results A1-A31, GenBank
- 2. Blast Results, B1-B7, Dayhoff

In accordance with 37 C.F.R. § 1.97(g),(h), this Information Disclosure Statement

is not to be construed as a representation that a search has been made and is not to be

construed to be an admission that the information cited is, or is considered to be,

material to patentability as defined in 37 C.F.R. § 1.56(b).

This Information Disclosure Statement is being filed prior to the receipt of the first

Official Action reflecting an examination on the merits and hence is believed to be timely

filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in

connection with filing of this Information Disclosure Statement, however, should any

fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to

these material, the Commissioner is hereby authorized to deduct said fees from Brinks

Hofer Gilson & Lione Deposit Account No. 23-1925. A duplicate copy of this document

is enclosed.

Applicant(s) respectfully request that the listed documents be made of record in

the present case.

Respectfully submitted,

Gregory M. Zinkl, Ph.D. Registration No. 48,492

Agent for Applicant(s)

BRINKS HOFER GILSON & LIONE P.O. Box 10395 Chicago, IL 60610 (312) 321-4200 Our Case No. 10466/131

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
Ashkenazi et al.)
Serial No. 09/944,862) Examiner To be assigned
Filing Date: August 31, 2001) Group Art Unit No. 1645
For SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS ENCODING THE SAME)))

RELEVANT PRIORITY DOCUMENTS

Commissioner for Patents Washington, D.C. 20231

Dear Sir:

The following priority documents are relevant to the presently claimed invention:

- 1. 60/075945; filed 2/25/1998
- 2. PCT/US98/25108; filed 12/1/1998
- 3. 09/254311; filed 3/3/1999
- 4. PCT/US99/28301; filed 12/1/1999

- 5. PCT/US00/05841; filed 3/2/2000
- 6. PCT/US00/08439;filed 3/30/2000
- 7. 09/866028; filed 5/25/2001

Respectfully submitted,

Gregory M. Zinkl, Ph.D. Registration No. 48,492

Agent for Applicant

BRINKS HOFER GILSON & LIONE P.O. BOX 10395 CHICAGO, ILLINOIS 60610 (312) 321-4200 PE VOIG

Document2

05-16-02

TRANSMITTAL LETTER Case No. 10466/131 Serial No. Filing Date Examiner **Group Art Unit** 09/944,862 August 31, 2001 1645 To be assigned Inventor(s) Ashkenazi et al. Title of Invention SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS ENCODING THE SAME TO THE COMMISSIONER FOR PATENTS Transmitted herewith is an Information Disclosure Statement; Form PTO-1449; 2 cited references; Statement regarding Relevant Priority Documents and return postcard. Small entity status of this application under 37 CFR § 1.27 has been established by verified statement previously submitted. A verified statement to establish small entity status under 37 CFR §§ 1.9 and 1.27 is enclosed. Petition for a _____month extension of time. No additional fee is required. The fee has been calculated as shown below: Other Than Small Entity Small Entity Claims Highest No. or Previously Present Add'l Add'i Remaining Paid For After Extra Rate Fee Rate Fee Amendment Total Minus x \$9= x \$18= x 42= Indep. Minus x \$84= +\$140= + \$280= First Presentation of Multiple Dep. Claim Total \$ Total \$ add'I fee add'I fee Please charge Deposit Account No. 23-1925 (BRINKS HOFER GILSON & LIONE) in the amount of \$_____. A duplicate copy of this sheet is enclosed. A check in the amount of \$ to cover the filing fee is enclosed. The Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 CFR § 1.16 and any patent application processing fees under 37 CFR § 1.17 associated with this communication or credit any overpayment to Deposit Account No. 23-1925. A duplicate copy of this sheet is enclosed. X I hereby petition under 37 CFR § 1.136(a) for any extension of time required to ensure that this paper is timely filed. Please charge any associated fees which have not otherwise been paid to Deposit Account No. 23-1925. A duplicate copy of this sheet is enclosed. Respectfully submitted. Gregory M. Zinkl, Ph Registration No. 48,492 Agent for Applicant **BRINKS HOFER GILSON & LIONE** P.O. BOX 10395 CHICAGO, ILLINOIS 60610 (312) 321-4200 I hereby certify that this correspondence is being deposited with the United States Postal Service as express mail, Express Mail Label No. EL 448312697US with sufficient postage, in an envelope address. Commissioner for Patents, Washington, D.C. 20231, on rev. Dec.-00